.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,750,497

« Back to Dashboard

Claims for Patent: 5,750,497

Title: Acylated insulin
Abstract:The present invention relates to human insulin derivatives having a protracted profile of action in which the A21 and B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the E-amino group of Lys.sup.B29 ; (b) any amino acid residue which can be coded by the genetic code except Lys, Arg and Cys, in which case a lipophilic substituent is bound to the E-amino group of Lys.sup.B29 ; or (c) deleted, in which case a lipophilic substituent is bound to the E-amino group of LyS.sup.B29 ; and any Zn.sup.2+ complexes thereof; provided that when the B30 amino acid residue is Thr or Ala, the A21 and B3 amino acid residues are both Asn and Phe.sup.B1 is present, then the insulin derivative is a Zn.sup.2 + complex.
Inventor(s): Havelund; Svend (Bagsv.ae butted.rd, DK), Halstr.o slashed.m; John (Hundested, DK), Jonassen; Ib (Valby, DK), Andersen; Asser Sloth (Frederiksberg C, DK), Markussen; Jan (Herlev, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:08/400,256
Patent Claims: 1. An insulin derivative having the following sequence: ##STR8## wherein (a) Xaa at positions A21 and B3 are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys;

(b) Xaa at position B1 is Phe or is deleted;

(c) Xaa at position B30 is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; and

(d) the .epsilon.-amino group of Lys.sup.B29 is substituted with an acyl group having at least 10 carbon atoms;

wherein insulin derivative is a Zn.sup.2 + complex and the Zn.sup.2 + complex of the insulin derivative is more water soluble than the insulin derivative without Zn.sup.2 +.

2. The insulin derivative according to claim 1, wherein Xaa at position A21 is Asn.

3. The insulin derivative according to claim 2, wherein the acyl group has from 12 to 24 carbon atoms.

4. The insulin derivative according to claim 1, wherein Xaa at position A21 is Ala, Asn, Gln, Gly or Ser.

5. The insulin derivative according to claim 4, wherein the acyl group has from 12 to 24 carbon atoms.

6. The insulin derivative according to claim 1, wherein Xaa at position B1 is deleted.

7. The insulin derivative according to claim 6, wherein the acyl group has from 12 to 24 carbon atoms.

8. The insulin derivative according to claim 1, wherein Xaa at position B1 is Phe.

9. The insulin derivative according to claim 8, wherein the acyl group has from 12 to 24 carbon atoms.

10. The insulin derivative according to claim 1, wherein Xaa at position B3 is Asn, Asp, Gln or Thr.

11. The insulin derivative according to claim 10, wherein the acyl group has from 12 to 24 carbon atoms.

12. The insulin derivative according to claim 1, wherein Xaa at position B30 is Ala or Thr.

13. The insulin derivative according to claim 12, wherein the acyl group has from 12 to 24 carbon atoms.

14. The insulin derivative according to claim 1, wherein Xaa at position A21 is Ala, Asn, Gln, Gly or Ser, Xaa at position B3 is Asn, Asp, Gln or Thr, and Xaa at position B30 is Ala or Thr.

15. The insulin derivative according to claim 14, wherein the acyl group has from 12 to 24 carbon atoms.

16. The insulin derivative according to claim 1, wherein Xaa at position A21 is Asn, Xaa at position B3 is Asn, Xaa at position B1 is Phe and Xaa at position B30 is Thr.

17. The insulin derivative according to claim 16, wherein the acyl has from 12 to 24 carbon atoms.

18. The insulin derivative according to claim 1, wherein the acyl group has from 12 to 24 carbon atoms.

19. The insulin derivative according to claim 18, wherein the acyl group is a linear, saturated acyl group.

20. The insulin derivative according to claim 19, wherein the acyl group is tetradecanoyl or hexadecanoyl.

21. The insulin derivative according to claim 1 which is N.sup..epsilon.B29 -decanoyl human insulin.

22. The insulin derivative according to claim 1 which is N.sup..epsilon.B29 -dodecanoyl human insulin.

23. The insulin derivative according to claim 1 which is N.sup..epsilon.B29 -tetradecanoyl human insulin.

24. The insulin derivative according to claim 1 which is N.sup..epsilon.B29 -lithocholoyl human insulin.

25. The insulin derivative according to claim 1 which is in the form of a hexamer.

26. The insulin derivative according to claim 25, wherein the acyl group has from 12 to 24 carbon atoms.

27. The insulin derivative according to claim 25, wherein Xaa at position A21 is Asn, Xaa at position B1 is Phe, Xaa at position B3 is Asn, and Xaa at position B30 is Thr.

28. The insulin derivative according to claim 25, wherein two zinc ions bind to the hexamer.

29. The insulin derivative according to claim 28, wherein the acyl group has from 12 to 24 carbon atoms.

30. The insulin derivative according to claim 25, wherein three zinc ions bind to the hexamer.

31. The insulin derivative according to claim 30, wherein the acyl group has from 12 to 24 carbon atoms.

32. The insulin derivative according to claim 25, wherein four zinc ions bind to the hexamer.

33. The insulin derivative according to claim 32, wherein the acyl group has from 12 to 24 carbon atoms.

34. A pharmaceutical composition which is an aqueous solution, comprising (a) an insulin derivative according to claim 1, (b) an isotonic agent, (c) a preservative and (d) a buffer.

35. The pharmaceutical composition according to claim 34, wherein the pH of the aqueous solution is in the range of 6.5-8.5.

36. The pharmaceutical composition according to claim 34, wherein the solubility of the insulin derivative exceeds 600 nmol/ml of the aqueous solution.

37. The pharmaceutical composition according to claim 34, further comprising an insulin or an insulin analogue which has a rapid onset of action.

38. The pharmaceutical composition according to claim 34, wherein Xaa at position A21 is Asn, Xaa at position B3 is Asn, Xaa at position Bi is Phe and Xaa at position B30 is Thr.

39. The pharmaceutical composition according to claim 34, wherein the acyl group has from 12 to 24 carbon atoms.

40. The pharmaceutical composition according to claim 39, wherein the acyl group is tetradecanoyl or hexadecanoyl.

41. The pharmaceutical composition according to claim 34, wherein the insulin derivative is N.sup..epsilon.B29 -decanoyl human insulin.

42. The pharmaceutical composition according to claim 34, wherein the insulin derivative is N.sup..epsilon.B29 -dodecanoyl human insulin.

43. The pharmaceutical composition according to claim 34, wherein the insulin derivative is N.sup..epsilon.B29 -tetradecanoyl human insulin.

44. The pharmaceutical composition according to claim 34, wherein the insulin derivative is N.sup..epsilon.B29 -lithocholoyl human insulin.

45. The pharmaceutical composition according to claim 34, wherein the insulin derivative is in the form of a hexamer.

46. A method of treating diabetes in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition according to claim 34.

47. An insulin derivative having the following sequence: ##STR9## wherein (a) Xaa at positions A21 and B3 are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys;

(b) Xaa at position B1 is Phe or is deleted;

(c) Xaa at position B30 is deleted; and

(d) the .epsilon.-amino group of Lys.sup.B29 is substituted with an acyl group having at least 10 carbon atoms;

wherein insulin derivative is a Zn.sup.2 + complex and the Zn.sup.2 + complex of the insulin derivative is more water soluble than the insulin derivative without Zn.sup.2 +.

48. The insulin derivative according to claim 47, wherein Xaa at position A21 is Ala, Asn, Gln, Gly or Ser.

49. The insulin derivative according to claim 48, wherein the acyl group has from 12 to 24 carbon atoms.

50. The insulin derivative according to claim 47, wherein Xaa at position B1 is deleted.

51. The insulin derivative according to claim 50, wherein the acyl group has from 12 to 24 carbon atoms.

52. The insulin derivative according to claim 47, wherein Xaa at position B1 is Phe.

53. The insulin derivative according to claim 52, wherein the acyl group has from 12 to 24 carbon atoms.

54. The insulin derivative according to claim 47, wherein Xaa at position B3 is Asn, Asp, Gln or Thr.

55. The insulin derivative according to claim 54, wherein the acyl group has from 12 to 24 carbon atoms.

56. The insulin derivative according to claim 47 wherein Xaa at position A21 is Ala, Asn, Gln, Gly or Ser, and Xaa at position B3 is Asn, Asp, Gln or Thr.

57. The insulin derivative according to claim 56, wherein the acyl group has from 12 to 24 carbon atoms.

58. The insulin derivative according to claim 47, wherein Xaa at position A21 is Asn, Xaa at position B13 is Phe, and Xaa at position B3 is Asn.

59. The insulin derivative according to claim 58, wherein the acyl group has from 12 to 24 carbon atoms.

60. The insulin derivative according to claim 47, wherein the acyl group has from 12 to 24 carbon atoms.

61. The insulin derivative according to claim 60, wherein the acyl group is a linear, saturated acyl group.

62. The insulin derivative according to claim 61, wherein the acyl group is tetradecanoyl or hexadecanoyl.

63. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -hexadecanoyl des(B30) human insulin.

64. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -tetradecanoyl des(B30) human insulin.

65. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -tridecanoyl des(B30) human insulin.

66. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -decanoyl, des(B30) insulin.

67. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -lithocholoyl.alpha.-glutamyl, des(B30) human insulin.

68. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -undecanoyl, des(B30) insulin.

69. The insulin derivative according to claim 47 which is N.sup..epsilon.B29 -dodecanoyl, des(B30) insulin.

70. The insulin derivative according to claim 47 which is in the form of a hexamer.

71. The insulin derivative according to claim 70, wherein the acyl group has from 12 to 24 carbon atoms.

72. The insulin derivative according to claim 70, wherein Xaa at position A21 is Asn, Xaa at position B3 is Asn, and Xaa at position B1 is Phe.

73. The insulin derivative according to claim 70, wherein two zinc ions bind to the hexamer.

74. The insulin derivative according to claim 73, wherein the acyl group has from 12 to 24 carbon atoms.

75. The insulin derivative according to claim 70, wherein three zinc ions bind to the hexamer.

76. The insulin derivative according to claim 75, wherein the acyl group has from 12 to 24 carbon atoms.

77. The insulin derivative according to claim 70, wherein four zinc ions bind to the hexamer.

78. The insulin derivative according to claim 77, wherein the acyl group has from 12 to 24 carbon atoms.

79. A pharmaceutical composition which is an aqueous solution, comprising (a) an insulin derivative according to claim 47; (b) an isotonic agent, (c) a preservative and (d) a buffer.

80. The pharmaceutical composition according to claim 79, wherein the pH of the aqueous solution is in the range of 6.5-8.5.

81. The pharmaceutical composition according to claim 79, wherein the solubility of the insulin derivative exceeds 600 nmol/ml of the aqueous solution.

82. The pharmaceutical composition according to claim 79, further comprising an insulin or an insulin analogue which has a rapid onset of action.

83. The pharmaceutical composition according to claim 79, wherein the insulin derivative is a Zn.sup.2 +complex.

84. The pharmaceutical composition according to claim 79, wherein Xaa at position A21 is Asn, Xaa at position B3 is Asn, and Xaa at position B1 is Phe.

85. The pharmaceutical composition according to claim 79, wherein the acyl group has from 12 to 24 carbon atoms.

86. The pharmaceutical composition according to claim 85, wherein the acyl group is tetradecanoyl or hexadecanoyl.

87. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -hexadecanoyl des(B30) human insulin.

88. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -tetradecanoyl des(B30) human insulin.

89. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -tridecanoyl des(B30) human insulin.

90. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -decanoyl, des(B30) insulin.

91. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -lithocholoyl-.alpha.-glutamyl, des(B30) human insulin.

92. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -undecanoyl, des(B30) insulin.

93. The pharmaceutical composition according to claim 79, wherein the insulin derivative is N.sup..epsilon.B29 -dodecanoyl, des(B30) insulin.

94. The pharmaceutical composition according to claim 79, wherein the insulin derivative is in the form of a hexamer.

95. A method of treating diabetes in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition according to claim 79.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc